Deepcure discovers oral STAT6 inhibitors for type 2 inflammatory diseases
Dec. 20, 2024
Deepcure Inc. has discovered potent, selective oral small-molecule inhibitors of STAT6. These next-generation STAT6 inhibitors have demonstrated promising oral bioavailability, cell permeability and metabolic stability, and do not target STAT6 for degradation.